Abstract
Huntington’s disease (HD) is an incurable neurodegenerative disorder that is characterized by motor dysfunction, cognitive impairment, and behavioral abnormalities. It is an autosomal dominant disorder caused by a CAG repeat expansion in the huntingtin gene, resulting in progressive neuronal loss predominately in the striatum and cortex. Despite the discovery of the causative gene in 1993, the exact mechanisms underlying HD pathogenesis have yet to be elucidated. Treatments that slow or halt the disease process are currently unavailable. Recent advances in induced pluripotent stem cell (iPSC) technologies have transformed our ability to study disease in human neural cells. Here, we firstly review the progress made to model HD in vitro using patient-derived iPSCs, which reveal unique insights into illuminating molecular mechanisms and provide a novel human cell-based platform for drug discovery. We then highlight the promises and challenges for pluripotent stem cells that might be used as a therapeutic source for cell replacement therapy of the lost neurons in HD brains.
Similar content being viewed by others
References
Walker FO (2007) Huntington's disease. Lancet 369(9557):218–228. doi:10.1016/s0140-6736(07)60111-1
Rikani AA, Choudhry Z, Choudhry AM, Rizvi N, Ikram H, Mobassarah NJ, Tulli S (2014) The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann Neurosci 21(3):112–114. doi:10.5214/ans.0972.7531.210308
Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83–98. doi:10.1016/S1474-4422(10)70245-3
Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord 27(9):1083–1091. doi:10.1002/mds.25075
Myers RH (2004) Huntington's disease genetics. NeuroRx 1(2):255–262. doi:10.1602/neurorx.1.2.255
Shannon KM, Fraint A (2015) Therapeutic advances in Huntington's disease. Mov Disord. doi:10.1002/mds.26331
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. doi:10.1016/j.cell.2006.07.024
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. doi:10.1016/j.cell.2007.11.019
Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y et al (2008) Generation of induced pluripotent stem cells without myc from mouse and human fibroblasts. Nat Biotechnol 26(1):101–106. doi:10.1038/nbt1374
Yamanaka S (2009) A fresh look at iPS cells. Cell 137(1):13–17. doi:10.1016/j.cell.2009.03.034
Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A et al (2007) Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9(6):625–635. doi:10.1038/ncb1589
Graham V, Khudyakov J, Ellis P, Pevny L (2003) SOX2 functions to maintain neural progenitor identity. Neuron 39(5):749–765. doi:10.1016/S0896-6273(03)00497-5
Dametti S, Faravelli I, Ruggieri M, Ramirez A, Nizzardo M, Corti S (2015) Experimental advances towards neural regeneration from induced stem cells to direct in vivo reprogramming. Mol Neurobiol:1–8. doi:10.1007/s12035-015-9181-7
Ross CA, Akimov SS (2014) Human-induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet 23(R1):R17–R26. doi:10.1093/hmg/ddu204
Choi SS, Lee SR, Kim SU, Lee HJ (2014) Alzheimer's disease and stem cell therapy. Exp Neurobiol 23(1):45–52. doi:10.5607/en.2014.23.1.45
Cao L, Tan L, Jiang T, Zhu XC, Yu JT (2015) Induced pluripotent stem cells for disease modeling and drug discovery in neurodegenerative diseases. Mol Neurobiol 52(1):244–255. doi:10.1007/s12035-014-8867-6
Upadhyay G, Shankar S, Srivastava RK (2015) Stem cells in neurological disorders: emerging therapy with stunning hopes. Mol Neurobiol 52(1):610–625. doi:10.1007/s12035-014-8883-6
Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 6(12):919–930. doi:10.1038/nrn1806
Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD et al (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81(5):811–823
Zuccato C, Cattaneo E (2014) Huntington's disease. Handb Exp Pharmacol 220:357–409. doi:10.1007/978-3-642-45106-5_14
Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90(3):905–981. doi:10.1152/physrev.00041.2009
Vonsattel JP (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115(1):55–69. doi:10.1007/s00401-007-0306-6
Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington's disease. Exp Neurol 238(1):1–11. doi:10.1016/j.expneurol.2011.12.013
Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ et al (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19(7):2522–2534
Cicchetti F, Lacroix S, Cisbani G, Vallieres N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper JN et al (2014) Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 76(1):31–42. doi:10.1002/ana.24174
Brustovetsky N (2015) Mutant huntingtin and elusive defects in oxidative metabolism and mitochondrial calcium handling. Mol Neurobiol. doi:10.1007/s12035-015-9188-0
Estrada Sanchez AM, Mejia-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 39(3):265–276. doi:10.1016/j.arcmed.2007.11.011
Sepers MD, Raymond LA (2014) Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. Drug Discov Today 19(7):990–996. doi:10.1016/j.drudis.2014.02.006
Cha JH (2007) Transcriptional signatures in Huntington's disease. Prog Neurobiol 83(4):228–248. doi:10.1016/j.pneurobio.2007.03.004
Valor L (2015) Transcription, epigenetics and ameliorative strategies in Huntington’s disease: a genome-wide perspective. Mol Neurobiol 51(1):406–423. doi:10.1007/s12035-014-8715-8
Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li XJ (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22(5):1277–1287
Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP et al (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97(12):6763–6768. doi:10.1073/pnas.100110097
Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, Takahashi H, Tsuji S et al (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291(5512):2423–2428. doi:10.1126/science.1056784
Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H et al (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448(7154):704–708. doi:10.1038/nature06022
Ortega Z, Lucas JJ (2014) Ubiquitin-proteasome system involvement in Huntington's disease. Front Mol Neurosci 7:77. doi:10.3389/fnmol.2014.00077
Sarkar S (2013) Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington's disease and other neurodegenerative disorders. Drug Discov Today Technol 10(1):e137–e144. doi:10.1016/j.ddtec.2012.09.010
Margulis J, Finkbeiner S (2014) Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease. Front Cell Neurosci 8:218. doi:10.3389/fncel.2014.00218
Cortes CJ, La Spada AR (2014) The many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapy. Drug Discov Today 19(7):963–971. doi:10.1016/j.drudis.2014.02.014
Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384(9942):545–555. doi:10.1016/s0140-6736(14)61010-2
Killoran A, Biglan KM (2014) Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? Mov Disord 29(11):1404–1413. doi:10.1002/mds.26014
Frank S (2014) Treatment of Huntington's disease. Neurotherapeutics 11(1):153–160. doi:10.1007/s13311-013-0244-z
Sampaio C, Borowsky B, Reilmann R (2014) Clinical trials in Huntington's disease: interventions in early clinical development and newer methodological approaches. Mov Disord 29(11):1419–1428. doi:10.1002/mds.26021
Aronin N, DiFiglia M (2014) Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 29(11):1455–1461. doi:10.1002/mds.26020
Godinho BM, Malhotra M, O'Driscoll CM, Cryan JF (2015) Delivering a disease-modifying treatment for Huntington's disease. Drug Discov Today 20(1):50–64. doi:10.1016/j.drudis.2014.09.011
Ostergaard ME, Kumar P, Nichols J, Watt A, Sharma PK, Nielsen P, Seth PP (2015) Allele-selective inhibition of mutant huntingtin with 2-Thio- and C5- triazolylphenyl-deoxythymidine-modified antisense oligonucleotides. Nucleic Acid Ther. doi:10.1089/nat.2015.0547
Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF et al (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther 19(12):2178–2185. doi:10.1038/mt.2011.201
Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 14(10):708–721. doi:10.1038/nrn3570
Figiel M, Szlachcic W, Switonski P, Gabka A, Krzyzosiak W (2012) Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol 46(2):393–429. doi:10.1007/s12035-012-8315-4
Merkle Florian T, Eggan K (2013) Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 12(6):656–668. doi:10.1016/j.stem.2013.05.016
Menalled L, Brunner D (2014) Animal models of Huntington's disease for translation to the clinic: best practices. Mov Disord 29(11):1375–1390. doi:10.1002/mds.26006
Zeng X, Hunsberger JG, Simeonov A, Malik N, Pei Y, Rao M (2014) Concise review: modeling central nervous system diseases using induced pluripotent stem cells. Stem Cells Transl Med 3(12):1418–1428. doi:10.5966/sctm.2014-0102
Nicoleau C, Viegas P, Peschanski M, Perrier AL (2011) Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges. Neurotherapeutics 8(4):562–576. doi:10.1007/s13311-011-0079-4
Kaye JA, Finkbeiner S (2013) Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 56:50–64. doi:10.1016/j.mcn.2013.02.005
Becanovic K, Norremolle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G et al (2015) A SNP in the HTT promoter alters NF-kappaB binding and is a bidirectional genetic modifier of Huntington disease. Nat Nuerosci 18(6):807–816. doi:10.1038/nn.4014
An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM (2012) Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11(2):253–263. doi:10.1016/j.stem.2012.04.026
Crane AT, Rossignol J, Dunbar GL (2014) Use of genetically altered stem cells for the treatment of Huntington's disease. Brain Sci 4(1):202–219. doi:10.3390/brainsci4010202
Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C et al (2008) Disease-specific induced pluripotent stem cells. Cell 134(5):877–886. doi:10.1016/j.cell.2008.07.041
Zhang N, An MC, Montoro D, Ellerby LM (2010) Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Currents 2:Rrn1193. doi:10.1371/currents.RRN1193
Chae JI, Kim DW, Lee N, Jeon YJ, Jeon I, Kwon J, Kim J, Soh Y et al (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J 446(3):359–371. doi:10.1042/bj20111495
Szlachcic WJ, Switonski PM, Krzyzosiak WJ, Figlerowicz M, Figiel M (2015) Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway. Dis Model Mech. doi:10.1242/dmm.019406
Camnasio S, Delli Carri A, Lombardo A, Grad I, Mariotti C, Castucci A, Rozell B, Lo Riso P et al (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 46(1):41–51. doi:10.1016/j.nbd.2011.12.042
Consortium THi (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11(2):264–278. doi:10.1016/j.stem.2012.04.027
Mattis VB, Tom C, Akimov S, Saeedian J, Ostergaard ME, Southwell AL, Doty CN, Ornelas L et al (2015) HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet. doi:10.1093/hmg/ddv080
Juopperi TA, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, Ming GL, Song H (2012) Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol Brain 5:17. doi:10.1186/1756-6606-5-17
Nagata E, Sawa A, Ross CA, Snyder SH (2004) Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. Neuroreport 15(8):1325–1328
Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C et al (2012) Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 30(9):2054–2062. doi:10.1002/stem.1135
An MC, O'Brien RN, Zhang N, Patra BN, De La Cruz M, Ray A, Ellerby LM (2014) Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR/Cas9 System. PLoS Curr 6. doi:10.1371/currents.hd.0242d2e7ad72225efa72f6964589369a
Yu DX, Marchetto MC, Gage FH (2013) Therapeutic translation of iPSCs for treating neurological disease. Cell Stem Cell 12(6):678–688. doi:10.1016/j.stem.2013.05.018
Peng J, Liu Q, Rao MS, Zeng X (2013) Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. J Biomol Screen 18(5):522–533. doi:10.1177/1087057112474468
Fecke W, Gianfriddo M, Gaviraghi G, Terstappen GC, Heitz F (2009) Small molecule drug discovery for Huntington's disease. Drug Discov Today 14(9–10):453–464. doi:10.1016/j.drudis.2009.02.006
Perrier A, Peschanski M (2012) How can human pluripotent stem cells help decipher and cure Huntington’s disease? Cell Stem Cell 11(2):153–161. doi:10.1016/j.stem.2012.07.015
Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A (2010) Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Curr Med Chem 17(8):759–766
Engle SJ, Puppala D (2013) Integrating human pluripotent stem cells into drug development. Cell Stem Cell 12(6):669–677. doi:10.1016/j.stem.2013.05.011
Rosser A, Svendsen CN (2014) Stem cells for cell replacement therapy: a therapeutic strategy for HD? Mov Disord 29(11):1446–1454. doi:10.1002/mds.26026
Chen Y, Carter RL, Cho IK, Chan AW (2014) Cell-based therapies for Huntington's disease. Drug Discov Today 19(7):980–984. doi:10.1016/j.drudis.2014.02.012
Bachoud-Levi A, Bourdet C, Brugieres P, Nguyen JP, Grandmougin T, Haddad B, Jeny R, Bartolomeo P et al (2000) Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 161(1):194–202. doi:10.1006/exnr.1999.7239
Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V et al (2000) Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356(9246):1975–1979
Philpott LM, Kopyov OV, Lee AJ, Jacques S, Duma CM, Caine S, Yang M, Eagle KS (1997) Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 6(3):203–212
Antoniades CA, Watts C (2013) Huntington's disease and cell therapies: past, present, and future. Methods Mol Biol 1010:19–32. doi:10.1007/978-1-62703-411-1_2
Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL (2008) Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 105(43):16707–16712. doi:10.1073/pnas.0808488105
Ma L, Hu B, Liu Y, Vermilyea SC, Liu H, Gao L, Sun Y, Zhang X et al (2012) Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 10(4):455–464. doi:10.1016/j.stem.2012.01.021
Delli Carri A, Onorati M, Lelos MJ, Castiglioni V, Faedo A, Menon R, Camnasio S, Vuono R et al (2013) Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 140(2):301–312. doi:10.1242/dev.084608
Fink KD, Crane AT, Leveque X, Dues DJ, Huffman LD, Moore AC, Story DT, Dejonge RE et al (2014) Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease. Stem Cells Transl Med 3(5):620–631. doi:10.5966/sctm.2013-0151
Mu S, Wang J, Zhou G, Peng W, He Z, Zhao Z, Mo C, Qu J et al (2014) Transplantation of induced pluripotent stem cells improves functional recovery in Huntington's disease rat model. PLoS One 9(7):e101185. doi:10.1371/journal.pone.0101185
Im W, Kim M (2014) Cell therapy strategies vs. paracrine effect in Huntington's disease. J Mov Disord 7(1):1–6. doi:10.14802/jmd.14001
Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J, Stewart H, McGee J et al (2012) Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 45(1):87–98. doi:10.1007/s12035-011-8219-8
Liu G, Rustom N, Litteljohn D, Bobyn J, Rudyk C, Anisman H, Hayley S (2014) Use of induced pluripotent stem cell derived neurons engineered to express BDNF for modulation of stressor related pathology. Front Cell Neurosci 8:316. doi:10.3389/fncel.2014.00316
Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, Baudic S, Ribeiro MJ et al (2006) Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 5(4):303–309. doi:10.1016/s1474-4422(06)70381-7
Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S et al (2013) The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 84(6):657–665. doi:10.1136/jnnp-2012-302441
Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, Li XJ, Parker JR et al (2009) Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 106(30):12483–12488. doi:10.1073/pnas.0904239106
Jeon I, Choi C, Lee N, Im W, Kim M, Oh SH, Park IH, Kim HS et al (2014) In vivo roles of a patient-derived induced pluripotent stem cell Line (HD72-iPSC) in the YAC128 model of Huntington's disease. Int J Stem Cells 7(1):43–47. doi:10.15283/ijsc.2014.7.1.43
Yang W, Dunlap JR, Andrews RB, Wetzel R (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11(23):2905–2917
Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 11(2):219–225. doi:10.1038/ncb1830
Herrera F, Tenreiro S, Miller-Fleming L, Outeiro TF (2011) Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr 3:Rrn1210. doi:10.1371/currents.RRN1210
Costanzo M, Abounit S, Marzo L, Danckaert A, Chamoun Z, Roux P, Zurzolo C (2013) Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J Cell Sci 126(Pt 16):3678–3685. doi:10.1242/jcs.126086
Pecho-Vrieseling E, Rieker C, Fuchs S, Bleckmann D, Esposito MS, Botta P, Goldstein C, Bernhard M et al (2014) Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat Neurosci 17(8):1064–1072. doi:10.1038/nn.3761
Pearce MM, Spartz EJ, Hong W, Luo L, Kopito RR (2015) Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the drosophila brain. Nat Commun 6:6768. doi:10.1038/ncomms7768
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China to T.W. (31171211 and 81471305), N.X. (81200983), and J.S.H. (81301082); a grant from China Medical Foundation to N.X. (2012B09); and a grant from Hubei Molecular Imaging Key Laboratory to N.X. (0203201343).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no competing interests.
Additional information
Ling Liu and Jin-Sha Huang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Liu, L., Huang, JS., Han, C. et al. Induced Pluripotent Stem Cells in Huntington’s Disease: Disease Modeling and the Potential for Cell-Based Therapy. Mol Neurobiol 53, 6698–6708 (2016). https://doi.org/10.1007/s12035-015-9601-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-015-9601-8